Zacks Investment Research on MSN

Will Keytruda remain the driving force behind Merck's Q2 performance?

Merck’s MRK blockbuster PD-1 inhibitor, Keytruda, approved for several types of cancer, is its key top-line driver, ...

What comes after Merck’s Keytruda? The race for the next standard cancer treatment.

Many think the next standard cancer treatment will pair two innovations.

FDA approves MSD’s Keytruda combinations for MIBC

The US Food and Drug Administration (FDA) has approved two of Merck & Co's (MSD) Keytruda (pembrolizumab) and Keytruda Qlex ...

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® ...

Merck posts late-stage trial win for frontline Keytruda in endometrial cancer

Merck (MRK) stock is in focus as the company posts a late-stage trial win for anti-PD-1 therapy, Keytruda, in endometrial cancer. Read more here.
FiercePharma

After Padcev combo’s major triumph, Merck’s Keytruda delivers partial win in bladder cancer

The combination of Merck's Keytruda and Pfizer and Astellas' Padcev recently made waves in bladder cancer—and the broader oncology world—by delivering a massive life-extension benefit against ...
Nasdaq

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
Cure Today

Trodelvy Plus Keytruda Upholds Quality of Life in TNBC

Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...
Cure Today

Postsurgical Keytruda Has Little Impact on Quality of Life in Melanoma

Keytruda did not significantly impact long-term health-related quality of life in stage 3 melanoma patients compared to placebo. Both Keytruda and placebo groups returned to baseline quality of life ...